Ensuring the Rigor of Regulatory Science: CDER Conducts Laboratory and Clinical Studies to Investigate Reports of NDMA Production from Ingested Ranitidine Products
Ranitidine, which blocks histamine-induced acid secretion in the stomach, was approved in 1983. It became widely used over the ensuing decades as a prescription and over-the-counter product. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 2, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

NPPA approves price rise of 50 per cent for carbamazepine, ranitidine, ibuprofen
NPPA, in its meeting on June 28, deliberated upon the case of upward price revision of the formulations of these drugs under Para 19 of DPCO 2013 and noted that the scheduled formulations being considered for upward price revision are low-priced drugs and have been under repeated price controls, it added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 2, 2021 Category: Pharmaceuticals Source Type: news

Heartburn Drug and Cancer: Does the Link Hold? Heartburn Drug and Cancer: Does the Link Hold?
Could this new wrinkle mean a return of ranitidine, a best-selling drug since the FDA approved it as Zantac in 1983?WebMD Health News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 22, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Widely Covered Paper on Ranitidine-Cancer Link Retracted Widely Covered Paper on Ranitidine-Cancer Link Retracted
The authors concluded that their widely touted finding appears to have resulted from a hiccup in the way they conducted their testing.Retraction Watch (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - June 15, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

FDA Updates and Press Announcements on NDMA in Ranitidine (Zantac)
FDA alerts health care professionals and patients to voluntary recall of ranitidine medicines (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 10, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Popular Heartburn Drugs Linked to Heightened COVID-19 Risk
A popular form of heartburn medication may increase a person’s risk of developing COVID-19, according to a new study, lengthening the already long list of risk factors for the virus. In the study, published Tuesday in pre-print form in the American Journal of Gastroenterology, scientists led by Cedars-Sinai Medical Center’s Dr. Brennan Spiegel conducted an online survey involving more than 86,000 people. Among them, more than 53,000 reported abdominal pain or discomfort, acid reflux, heartburn or regurgitation, and answered questions about the medications they took to relieve those symptoms. Of those, more than...
Source: TIME: Health - July 7, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Zantac, Ranitidine Pulled From Market, Here Are FDA ’s Latest Cancer Concerns
New findings about N-Nitrosodimethylamine (NDMA) contamination of this type of heartburn medication led to the U.S. Food and Drug Administration's (FDA's) more drastic action. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 2, 2020 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news

FDA Calls for Market Removal of Ranitidine FDA Calls for Market Removal of Ranitidine
The agency found through product testing that NDMA contamination in ranitidine, commonly known by the brand name Zantac, can develop over time when the product is stored above room temperature.News Alerts (Source: Medscape Pulmonary Medicine Headlines)
Source: Medscape Pulmonary Medicine Headlines - April 2, 2020 Category: Respiratory Medicine Tags: Gastroenterology News Alert Source Type: news

FDA calls for Zantac products to be pulled from market immediately
The US Food and Drug Administration is requesting that manufacturers pull all prescription and over-the-counter ranitidine drugs, known by the brand name Zantac, from the market immediately, the agency announced on Wednesday. (Source: CNN.com - Health)
Source: CNN.com - Health - April 2, 2020 Category: Consumer Health News Source Type: news

FDA Requests Zantac Be Pulled From the Market
Six months after independent testing first raised the possibility that popular heartburn drug ranitidine (Zantac) might break down into the powerful carcinogen n-nitrosodimethylamine (NDMA), the FDA has asked for the removal of all ranitidine products from the market. (Source: WebMD Health)
Source: WebMD Health - April 2, 2020 Category: Consumer Health News Source Type: news

FDA calls for heartburn drug Zantac to be pulled from market immediately
The US Food and Drug Administration is requesting that manufacturers pull all prescription and over-the-counter ranitidine drugs, known by the brand name Zantac, from the market immediately, the agency announced on Wednesday. (Source: CNN.com - Health)
Source: CNN.com - Health - April 1, 2020 Category: Consumer Health News Source Type: news

FDA Pulls Heartburn Drug Zantac From Market
WEDNESDAY, April 1, 2020 -- All versions of the heartburn drug Zantac (ranitidine) have been pulled from the U.S. market due to possible contamination with a probable human carcinogen, the U.S. Food and Drug Administration said Wednesday. This is... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 1, 2020 Category: Pharmaceuticals Source Type: news

FDA orders Zantac, other heartburn drugs removed from market due to NDMA contamination
The U.S. Food and Drug Administration ordered drugmakers to remove all prescription and over-the-counter products containing the agent ranitidine from the market immediately due to possible contamination. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 1, 2020 Category: Consumer Health News Source Type: news

FDA Calls For Heartburn Drug Zantac To Be Pulled From Market Immediately
(CNN) — The US Food and Drug Administration is requesting that manufacturers pull all prescription and over-the-counter ranitidine drugs, known by the brand name Zantac, from the market immediately, the agency announced on Wednesday. The FDA noted that an ongoing investigation has determined that levels of a contaminant in the heartburn medications increase over time and when stored at higher-than-normal temperatures, poses a risk to public health. The contaminant, N-nitrosodimethylamine or NDMA, is a probable human carcinogen and the FDA has been investigating levels of it in ranitidine since the summer of 2019. &ld...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 1, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Syndicated CBSN Boston CNN Zantac Source Type: news

All Ranitidine Products (Zantac): Press Release - FDA Requests Removal
The FDA announced it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 1, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

U.S. FDA moves to remove all versions of heartburn drug Zantac from market
Ranitidine will not be available for use in the U.S. after the FDA pulls all remaining prescription and over-the-counter products containing the ingredient found in the heartburn medication Zantac. (Source: CBC | Health)
Source: CBC | Health - April 1, 2020 Category: Consumer Health News Tags: News/Health Source Type: news

FDA Pulls Heartburn Drug Zantac From Market
WEDNESDAY, April 1, 2020 -- All versions of the heartburn drug Zantac (ranitidine) have been pulled from the U.S. market due to possible contamination with a probable cancer-causing chemical, the U.S. Food and Drug Administration said... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 1, 2020 Category: General Medicine Source Type: news

Class 2 medicines recall: Ranitidine 150mg and 300mg tablets
Medreich Plc is recalling all unexpired stock of ranitidine 150mg and 300mg tablets from pharmacies and wholesalers as a precautionary measure due to possible contamination with an impurity N-nitrosod (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - February 3, 2020 Category: Drugs & Pharmacology Source Type: news

Granules India says 'voluntarily' recalling ranitidine tabs
Granules India has said that it has received multiple queries on the news item for recall of ranitidine by the drug firm. The company is in the process of recall from channel partners and the exact quantities are being estimated. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 12, 2020 Category: Pharmaceuticals Source Type: news

Three more heartburn drugs recalled over carcinogen fears
This week, the FDA announced recalls of Zantac generics made by Appco Pharma, Northwind and Mylan's non-ranitidine heartburn drug nizatdine. A California lab thinks heat triggers NDMA's creation. (Source: the Mail online | Health)
Source: the Mail online | Health - January 10, 2020 Category: Consumer Health News Source Type: news

Lab investigates heartburn drug ’s possible cancer link
The popular heartburn drug ranitidine, the generic form of Zantac, was linked to cancer in September, prompting some voluntary recalls of the drug and an investigation by the FDA. A lab in California has also been working to get to the bottom of its potential dangers. First on “CBS This Morning,” Dr. Jon LaPook has a look inside that lab. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - January 10, 2020 Category: Consumer Health News Source Type: news

Denton Pharma, Inc. dba Northwind Pharmaceuticals Voluntarily Recalls All Unexpired Lots of its Ranitidine Tablets and Ceases Distribution, Due to Possible Presence of N-nitrosodimethylamine (NDMA) Impurity
Denton Pharma, Inc. dba Northwind Pharmaceuticals, an affiliate of Northwind Pharmaceuticals, LLC ( “Northwind”) today announced the voluntary recall of all unexpired lots of Ranitidine Tablets, 150 mg and 300mg, to the consumer level. The recall is in response to the manufacturer’s recall of all un (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 8, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Appco Pharma LLC Issues Voluntary Nationwide Recall of Ranitidine Hydrochloride Capsules 150 mg and 300 mg Due to an Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA)
Appco Pharma LLC (Appco) is voluntarily recalling all quantities and lots, within expiry, of Ranitidine Hydrochloride Capsules to the Consumer level. Ranitidine Hydrochloride Capsules are being recalled because of the presence or potential presence of N-nitrosodimethylamine (NDMA) (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 7, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Supply Disruption Alert Update – Ranitidine: all formulations
The Department of Health and Social Care (DHSC) has issued an update to its previous Supply Disruption Alert. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - December 23, 2019 Category: Drugs & Pharmacology Source Type: news

Glenmark Pharmaceutical Inc recalls ranitidine tablets in US
The tablets are being recalled because of the presence or potential presence of N-nitrosodimethylamine (NDMA) levels above the acceptable daily intake levels established by the United States Food and Drug Administration (USFDA), as per the company's announcement posted on the website of the US health regulator. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 21, 2019 Category: Pharmaceuticals Source Type: news

Glenmark Pharmaceuticals Inc., USA Voluntarily Recalls All Unexpired Lots of its Ranitidine Tablets and Ceases Distribution, Due to Possible Presence of N-nitrosodimethylamine (NDMA) Impurity
Glenmark Pharmaceutical Inc., USA ( “Glenmark”) today announced the voluntary recall of all unexpired lots of Ranitidine Tablets, 150 mg and 300 mg, to the consumer level. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 18, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Class 2 Medicines Recall: Medley Pharma Limited, Ranitidine 150mg Tablets BP, PL 43870/0026, Ranitidine 300mg Tablets BP, PL 43870/0027
Medley Pharma Limited is... (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - December 16, 2019 Category: Drugs & Pharmacology Source Type: news

Class 2 Medicines recall: Ranitidine 150mg Film-Coated Tablets, PL 20075/0063, Ranitidine 300mg Film-Coated Tablets, PL 20075/0064
Accord Healthcare are recalling all unexpired stock of the Ranitidine 150mg Film-Coated Tablets and Ranitidine 300mg Film-Coated Tablets products from pharmacies, retail stores and wholesalers as a pr (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - December 5, 2019 Category: Drugs & Pharmacology Source Type: news

Class 2 Medicines recall: Ranitidine 150mg Film-Coated Tablets, PL 20075/0063, Ranitidine 300mg Film-Coated Tablets, PL 20075/0064
Accord Healthcare are recalling all unexpired stock of the above products from pharmacies, retail stores and wholesalers as a precautionary measure, due to possible contamination with an impurityN-nit (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - December 5, 2019 Category: Drugs & Pharmacology Source Type: news

Class 2 Medicines recall: Ranitidine 150mg Film-Coated Tablets, PL 20075/0063, Ranitidine 300mg Film-Coated Tablets, PL 20075/0064
Accord Healthcare are recalling all unexpired stock of the Ranitidine 150mg Film-Coated Tablets and Ranitidine 300mg Film-Coated Tablets products from pharmacies, retail stores and wholesalers as a pr (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - December 5, 2019 Category: Drugs & Pharmacology Source Type: news

Doctors must stop prescribing Zantac until further notice, Department of Health says
The Department of Health and Social Care (DoHS) said stock of ranitidine said all versions of ranitidine had been quarantined. It has banned UK GPs from prescribing them. (Source: the Mail online | Health)
Source: the Mail online | Health - November 29, 2019 Category: Consumer Health News Source Type: news

Ranitidine: all formulations – Supply Disruption Alert – Update
The Department of Health and Social Care (DHSC) has updated their advice of a supply disruption of all formulations of ranitidine. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - November 28, 2019 Category: Drugs & Pharmacology Source Type: news

Zantac Recall: Does Ranitidine Cause Cancer?
Late September 2019, Valisure filed a Citizen Petition urging the FDA to recall ranitidine. Although several drug companies and major drug store chains quickly suspended sales of Zantac and its generic ranitidine voluntarily, the FDA did not issue... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 26, 2019 Category: General Medicine Source Type: news

From Licorice to Slippery Elm: What Works for GI Symptoms? From Licorice to Slippery Elm: What Works for GI Symptoms?
In the wake of recent concerns with ranitidine, Dr David Johnson shares the evidence (or lack thereof) for some popular alternative remedies that patients may turn to for upper GI diseases like reflux.Medscape Gastroenterology (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 22, 2019 Category: Gastroenterology Tags: Gastroenterology Commentary Source Type: news

Tanzania: Tanzania Agency Bans Ranitidine-Based Drugs
[East African] The state-run Tanzania Medicines and Medical Devices Authority (TMDA) has suspended the use of medicines containing the active pharmaceutical ingredient Ranitidine until further notice. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - November 22, 2019 Category: African Health Source Type: news

Class 2 medicines recall: Ranitidine 75mg tablets
OTC Concepts Ltd, Relconchem Ltd and Noumed Life Sciences Ltd are recalling all unexpired batches of the products mentioned in the MHRA alert from pharmacies and retail stores as a precautionary measu (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - November 21, 2019 Category: Drugs & Pharmacology Source Type: news